Anyone have an idea on timing of the preclinical for other neurodegenerative disorders?
AD driven by amyloid plaque and tau aggregation are reduced by mTor inhibition. Monepantel is a potent mTor inhibitor, not hard to put two and two together.
Wonder how the market will respond we would double the opportunity for PAA.
Phase II Begins, Cashed Up with Healey In the Sights of Big Pharma $$$, page-62
-
- There are more pages in this discussion • 224 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add PAA (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
17.3¢ |
Change
-0.008(4.17%) |
Mkt cap ! $83.90M | |||
| Open | High | Low | Value | Volume |
| 18.0¢ | 18.0¢ | 17.3¢ | $59.77K | 338.7K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 13 | 376984 | 17.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 17.5¢ | 25091 | 2 |
View Market Depth
| Last trade - 15.42pm 13/09/2024 (20 minute delay) ? |
| PAA (ASX) Chart |